Loading...
Market
First TRPC5-targeting treatment to reach Phase 2 trials for?
3
Resolution / Starting Odds
Obesity • 33%
Postnatal Depression • 33%
Both • 33%
ClinicalTrials.gov or official announcements from research institutions
Story
TRPC5 Gene Linked to Obesity, Postnatal Depression, and Infants' Mental Health
Jul 2, 2024, 06:57 PM
Recent research has highlighted the role of the TRPC5 gene in obesity and postnatal depression. Scientists from the University of Cambridge and Baylor College of Medicine have discovered that impairments in the TRPC5 gene can disrupt oxytocin neurons, which are crucial for regulating behaviors related to food seeking and maternal care. Follow-up studies in mice suggest that oxytocin, often referred to as the 'love hormone,' may help alleviate symptoms of postnatal depression and obesity. Additionally, hormones associated with body composition during pregnancy have been linked to infants' mental health. This discovery opens new avenues for potential treatments targeting the TRPC5 gene and oxytocin pathways.
View original story
Similar markets
Prion Diseases • 33%
Parkinson's Disease • 33%
Alzheimer's Disease • 33%
Huntington's Disease • 25%
ALS • 25%
Duchenne Muscular Dystrophy • 25%
Other • 25%
Yes • 50%
No • 50%
ARO-DUX4 • 25%
ARO-MMP7 • 25%
Other program • 25%
No program reaches Phase 2 • 25%
Respiratory drug • 25%
Immunology drug • 25%
Vaccine • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Phase 2 Trial Completion • 25%
FDA Approval • 25%
Commercial Launch • 25%
None of the Above • 25%
Yes • 50%
No • 50%
Initiated before January 1, 2025 • 25%
Initiated between January 1, 2025 and March 31, 2025 • 25%
Initiated between April 1, 2025 and June 30, 2025 • 25%
Not initiated by June 30, 2025 • 25%